VINCO, Inc. – Trademark Portfolio

Entity Type: 03

VINCO, Inc. holds 41 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 40 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 2 Nice Classification classes. Currently, 14 trademarks are registered and 1 is pending. Notable registered marks include GOUTCH, N2GOUT, HIMEGA-3, GLUKOKINE, and INJURECOV. The owner is based in Evans City, PA.

1519 Mars-Evans City Road

Evans City, PA 16033

41 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (41 results)

Trademark Classifications

VINCO, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (40 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

40
Treatment & Processing (1 filing)

Treatment of materials

Frequently Asked Questions

How many trademarks does VINCO, Inc. have?

VINCO, Inc. has 41 U.S. trademarks filed with the USPTO. Of these, 14 registered, 1 pending, 17 abandoned, 9 cancelled.

What trademark classes does VINCO, Inc. file in?

VINCO, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are VINCO, Inc.'s most well-known trademarks?

VINCO, Inc.'s registered trademark portfolio includes well-known marks such as GOUTCH, N2GOUT, HIMEGA-3, GLUKOKINE, and INJURECOV. These are among 14 currently registered trademarks in the portfolio.

What is VINCO, Inc.'s trademark registration success rate?

VINCO, Inc. has a 35% trademark registration rate, with 14 out of 40 resolved applications resulting in successful registration. Currently, 1 application is pending review.